CY1110862T1 - Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης - Google Patents
Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινηςInfo
- Publication number
- CY1110862T1 CY1110862T1 CY20101100972T CY101100972T CY1110862T1 CY 1110862 T1 CY1110862 T1 CY 1110862T1 CY 20101100972 T CY20101100972 T CY 20101100972T CY 101100972 T CY101100972 T CY 101100972T CY 1110862 T1 CY1110862 T1 CY 1110862T1
- Authority
- CY
- Cyprus
- Prior art keywords
- basic protein
- myelin basic
- peptides
- immune tolerance
- induce immune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Παρέχεται ένα πεπτίδιο το οποίο είναι δυνάμενο δέσμευσης σε ένα μόριο MHC τάξης I ή II χωρίς περαιτέρω κατεργασία (δηλ. ένας απίτοπος) το οποίο περιλαμβάνει ένα τμήμα της περιοχής (131-158) της βασικής πρωτεΐνης της μυελίνης, ειδικότερα δε παρέχεται ένας απίτοπος ο οποίος επιλέγεται από τα κάτωθι πεπτίδια της βασικής πρωτεΐνης της μυελίνης: (134-148, 135-149, 136-150, 137-151, 138-152, 139-153, 140-154). Επίσης παρέχεται η χρήση ενός πεπτιδίου αυτού του είδους σε μια φαρμακευτική σύνθεση και μια μέθοδος για την αγωγή και/ή την πρόληψη μια πάθησης χρησιμοποιώντας ένα πεπτίδιο αυτού του είδους.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0202399.2A GB0202399D0 (en) | 2002-02-01 | 2002-02-01 | Peptide |
EP03701612A EP1474443B1 (en) | 2002-02-01 | 2003-01-30 | Tolerogenic peptides from myelin basic protein |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110862T1 true CY1110862T1 (el) | 2015-06-10 |
Family
ID=9930251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20101100972T CY1110862T1 (el) | 2002-02-01 | 2010-10-27 | Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης |
Country Status (24)
Country | Link |
---|---|
US (1) | US7071297B2 (el) |
EP (1) | EP1474443B1 (el) |
JP (1) | JP4559082B2 (el) |
KR (1) | KR20040108650A (el) |
CN (1) | CN100482685C (el) |
AT (1) | ATE477269T1 (el) |
AU (1) | AU2003202701B2 (el) |
BR (1) | BRPI0307276B8 (el) |
CA (1) | CA2473469C (el) |
CO (1) | CO5601035A2 (el) |
CY (1) | CY1110862T1 (el) |
DE (1) | DE60333728D1 (el) |
DK (1) | DK1474443T3 (el) |
ES (1) | ES2349463T3 (el) |
GB (1) | GB0202399D0 (el) |
HK (1) | HK1066551A1 (el) |
MX (1) | MXPA04007510A (el) |
NO (1) | NO332446B1 (el) |
NZ (1) | NZ534233A (el) |
PL (1) | PL212129B1 (el) |
PT (1) | PT1474443E (el) |
SI (1) | SI1474443T1 (el) |
WO (1) | WO2003064464A1 (el) |
ZA (1) | ZA200405546B (el) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1311542E (pt) | 2000-08-21 | 2008-10-03 | Apitope Technology Bristol Ltd | Péptidos tolerogénicos |
WO2008121836A1 (en) * | 2007-03-30 | 2008-10-09 | Brigham And Women's Hospital, Inc. | Compounds and methods for enhancing mhc class ii therapies |
SI2211892T1 (sl) * | 2007-10-31 | 2011-12-30 | Apitope Technology Bristol Ltd | Sestavki, ki obsegajo peptide mielinskega bazičnega proteina in njihove medicinske uporabe |
WO2011046462A1 (en) | 2009-10-12 | 2011-04-21 | Angport Limited | Composition for treatment of multiple sclerosis |
US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
CN108129554A (zh) | 2010-08-10 | 2018-06-08 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
GB201314052D0 (en) | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
SG11201606761RA (en) | 2014-02-21 | 2016-09-29 | Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
US10646589B2 (en) | 2014-12-24 | 2020-05-12 | Apitope International Nv | Thyroid stimulating hormone receptor peptides and uses thereof |
EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
CA3049177A1 (en) * | 2017-01-04 | 2018-07-12 | Apitope Technology (Bristol) Limited | Therapeutic method using tolerogenic peptides |
WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
CN110317254A (zh) * | 2018-03-28 | 2019-10-11 | 深圳市安群生物工程有限公司 | 人mbp抗原表位肽、抗原、抗体、应用及化学发光试剂盒 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077509A (en) * | 1990-03-30 | 2000-06-20 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
SI9520059A (en) * | 1994-05-10 | 1997-08-31 | Immulogic Pharma Corp | Compositions and treatment for multiple sclerosis. |
AU4278296A (en) * | 1994-10-25 | 1996-05-15 | Immulogic Pharmaceutical Corporation | Compositions and treatment for multiple sclerosis |
PT1311542E (pt) * | 2000-08-21 | 2008-10-03 | Apitope Technology Bristol Ltd | Péptidos tolerogénicos |
-
2002
- 2002-02-01 GB GBGB0202399.2A patent/GB0202399D0/en not_active Ceased
-
2003
- 2003-01-30 AU AU2003202701A patent/AU2003202701B2/en not_active Ceased
- 2003-01-30 CN CNB038030772A patent/CN100482685C/zh not_active Expired - Fee Related
- 2003-01-30 AT AT03701612T patent/ATE477269T1/de active
- 2003-01-30 WO PCT/GB2003/000399 patent/WO2003064464A1/en active Application Filing
- 2003-01-30 PL PL371549A patent/PL212129B1/pl unknown
- 2003-01-30 MX MXPA04007510A patent/MXPA04007510A/es active IP Right Grant
- 2003-01-30 CA CA2473469A patent/CA2473469C/en not_active Expired - Lifetime
- 2003-01-30 SI SI200331890T patent/SI1474443T1/sl unknown
- 2003-01-30 ES ES03701612T patent/ES2349463T3/es not_active Expired - Lifetime
- 2003-01-30 KR KR10-2004-7011906A patent/KR20040108650A/ko not_active Application Discontinuation
- 2003-01-30 EP EP03701612A patent/EP1474443B1/en not_active Expired - Lifetime
- 2003-01-30 BR BRPI0307276A patent/BRPI0307276B8/pt not_active IP Right Cessation
- 2003-01-30 JP JP2003564084A patent/JP4559082B2/ja not_active Expired - Fee Related
- 2003-01-30 DK DK03701612.8T patent/DK1474443T3/da active
- 2003-01-30 PT PT03701612T patent/PT1474443E/pt unknown
- 2003-01-30 NZ NZ534233A patent/NZ534233A/en not_active IP Right Cessation
- 2003-01-30 DE DE60333728T patent/DE60333728D1/de not_active Expired - Lifetime
-
2004
- 2004-07-13 ZA ZA2004/05546A patent/ZA200405546B/en unknown
- 2004-07-27 US US10/900,032 patent/US7071297B2/en not_active Expired - Lifetime
- 2004-07-28 NO NO20043210A patent/NO332446B1/no not_active IP Right Cessation
- 2004-08-26 CO CO04083647A patent/CO5601035A2/es not_active Application Discontinuation
- 2004-11-27 HK HK04109379.8A patent/HK1066551A1/xx not_active IP Right Cessation
-
2010
- 2010-10-27 CY CY20101100972T patent/CY1110862T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
BR0307276A (pt) | 2004-12-14 |
BRPI0307276B8 (pt) | 2021-05-25 |
JP4559082B2 (ja) | 2010-10-06 |
JP2005531497A (ja) | 2005-10-20 |
SI1474443T1 (sl) | 2010-12-31 |
HK1066551A1 (en) | 2005-03-24 |
NO332446B1 (no) | 2012-09-17 |
CA2473469A1 (en) | 2003-08-07 |
ZA200405546B (en) | 2005-09-28 |
US20050058643A1 (en) | 2005-03-17 |
CN100482685C (zh) | 2009-04-29 |
US7071297B2 (en) | 2006-07-04 |
CA2473469C (en) | 2012-04-24 |
WO2003064464A1 (en) | 2003-08-07 |
MXPA04007510A (es) | 2005-07-13 |
PL212129B1 (pl) | 2012-08-31 |
CN1625564A (zh) | 2005-06-08 |
DK1474443T3 (da) | 2010-10-18 |
NO20043210L (no) | 2004-11-01 |
AU2003202701B2 (en) | 2009-01-08 |
DE60333728D1 (de) | 2010-09-23 |
KR20040108650A (ko) | 2004-12-24 |
PL371549A1 (en) | 2005-06-27 |
PT1474443E (pt) | 2010-10-26 |
EP1474443A1 (en) | 2004-11-10 |
GB0202399D0 (en) | 2002-03-20 |
ATE477269T1 (de) | 2010-08-15 |
NZ534233A (en) | 2006-04-28 |
EP1474443B1 (en) | 2010-08-11 |
BRPI0307276B1 (pt) | 2019-08-13 |
ES2349463T3 (es) | 2011-01-03 |
CO5601035A2 (es) | 2006-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110862T1 (el) | Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης | |
PH12013500208A1 (en) | Tolerogenic peptides from myelin basic priotein | |
SE0103754L (sv) | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid | |
BR9814276A (pt) | Antìgenos de superfìcie | |
IL173952A0 (en) | Anti-angiogenic peptides and pharmaceutical compositions based thereon | |
EA200600128A1 (ru) | Способ уничтожения раковых клеток (варианты), фармацевтическое средство (варианты) и набор для его осуществления | |
BRPI0414157A (pt) | polipeptìdeo isolado, ácido nucleico isolado, método para inibir a infecção por vìrus da sìndrome da mancha branca de um crustáceo, e, alimento para um crustáceo | |
DE60322559D1 (de) | Neue, mhc klasse ii assoziierte peptide | |
ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
DE3584775D1 (de) | Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken. | |
HUP0001458A2 (hu) | Specifikus hasnyálmirigy lipáz inhibitor hatású peptidek, ezeket tartalmazó gyógyszerkészítmények és diagnosztikai reagensek, valamint ezek alkalmazása |